Nemaura Pharma, the fast-growing UK medical technology company, is a finalist in the Medilink UK industry awards having received the Medilink East Midlands Innovation award for its unique transdermal drug delivery technologies.
Included in the award citation is the Nemaura patented Micro-Patch product, which provides a highly consistent and effective method for better delivery of biologics and vaccines through the skin using a low cost disposable device.
This latest recognition by life science sector experts comes just a year after Frost & Sullivan, the global growth strategy analysts, identified Nemaura’s drug delivery technologies as having the potential to revolutionise the way drugs are delivered into the body.
Nemaura aims to be one of the leading pharmaceutical technologists in the skin drug delivery market, which is expected to grow at around 12% to a global value of more than $95 billion by 2025.
Dr Faz Chowdhury, Founding Director, commented: “Winning this Innovation Award has capped a busy and productive year for us. We have exciting plans for next year as we look to further expand the range of vaccines and biologics the Micro-Patch can deliver, and we are confident about engaging several new partners following the overwhelming response from potential licensees at this year’s BIO International Convention in San Diego.”
Nemaura joined the delegation to BIO 2017 which was supported by the Department for International Trade (DIT) and the development organisation, Midlands Engine.
Simon Hall, Director Exports & Investment Midlands Engine, said: “We are delighted that Nemaura are finalists in the Medilink UK industry awards which is a richly deserved achievement. Their pioneering pharmaceutical products are widely recognised across the sector for their innovation and this was further reinforced by the huge interest that was shown in them during the recent Midlands Engine visit to Bio 2017 in San Diego.”
“The Midlands has an enviable reputation for pharma and healthcare, and the Department for International Trade will continue to work hard with companies in this field to help them exploit their expertise on the global stage.”
Worldwide interest in Nemaura is being managed by the respected pharmaceutical expert and deal-maker, Dr Werner Westling, who joined the team in April this year as Director of Strategic Alliances. His industry insight and extensive networks will make a significant contribution with annual license and royalty revenue expected to double by 2019.
Founded in 2005, Nemaura has patents secured or pending across multiple patent families and employs a multidisciplinary team of medical device technologists and formulation experts based on the Loughborough University Science and Enterprise Park. Ambitious expansion plans mean the company is set to employ more than 200 people by 2025.
Dr Chowdhury explains: “With 22 drugs in development or commercialisation, we are targeting revenues of more than £100 million by 2025. Accolades from the likes of Frost & Sullivan and Medilink validate we are on the right track to commercial growth and success.”